Sunday, 28 February 2021

4baseCare, Tata Memorial Centre to develop AI based clinical interpretation platform

09 January 2021 | News

This AI driven tool will support oncologist in clinical decision making and to offer precision medicine to cancer patients

Image credit- shutterstock.com

Image credit- shutterstock.com

4baseCare, an Illumina Accelerator backed precision oncology startup in Bengaluru and ACTREC (Advanced Centre for Treatment, Research and Education in Cancer) - Tata Memorial Centre (TMC) in Mumbai have signed a collaboration agreement for an AI driven clinical interpretation platform, ClinOme. 

The collaboration aims at making an indigenous platform to generate data insights and simplified reports to guide oncologists with personalised treatment options for treating cancer patients.  

ClinOme is a Graphical User Interface (GUI) based automated tool developed by senior scientists & clinicians from ACTREC & Tata Memorial Hospital by Dr. Amit Dutt, Dr. Pratik Chandrani and Dr. Kumar Prabhash for analysis of raw NGS data followed by comprehensive clinical report generation. It automates quality check, primary, secondary and tertiary analysis of raw NGS data followed by report generation that can be easily comprehended by the clinicians. It provides easy to interpret categorization of genomic alterations along with approved and experimental therapeutic options for each responsive and resistant genotype-drug combination.

4baseCare having an exclusive worldwide license to ClinOme, plans to invest significant time and resources to further develop and enhance the functionality and precision of ClinOme.

This collaboration will set a great precedence for industry-academia collaboration towards translational research. It will also be a huge step towards personalisation of treatment for Indian cancer patients and aligns with the vision of both ACTREC-TMC and 4baseCare of improving quality of life and treatment of cancer patients of the country.   

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls